The current socioeconomic and regulatory landscape of immune effector cell therapies
C Sainatham, D Yadav, A Dilli Babu… - Frontiers in …, 2024 - frontiersin.org
Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …
Talicabtagene Autoleucel: First Approval
T Nie - Molecular Diagnosis & Therapy, 2024 - Springer
Talicabtagene autoleucel (NexCAR19™) is a chimeric antigen receptor (CAR) T-cell therapy
being developed by the Indian Institute of Technology, Bombay (IIT-B) and Immunoadoptive …
being developed by the Indian Institute of Technology, Bombay (IIT-B) and Immunoadoptive …
[PDF][PDF] Childhood Cancer in India: Miles to Go Before We Sleep!
P Dewan, P Jain, M Trivedi - Indian Pediatrics, 2023 - researchgate.net
1Department of Pediatrics, University College of Medical Sciences, Delhi. 2Department of
Pediatric Oncology and Hematology and BMT, Max Super Speciality Hospital, Vaishali …
Pediatric Oncology and Hematology and BMT, Max Super Speciality Hospital, Vaishali …